INTRODUCTION
Breast cancer is the most common type of cancer in women and despite combination of therapies it might relapse in more than half of the cases [1] . The time interval between initial diagnosis and distant metastases can be up to many years [2] .
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Key words: breast carcinoma -metastases -linitis plastica -estrogen receptors -anti-GATA-binding protein 3 (GATA3) nuclear antibodies. uterus or the ovaries [6] . Lobular carcinoma of the breast has more affinity to the gastrointestinal tract than the other types [4] , with an incidence of 4.5% compared to 0.2% in ductal carcinoma [7] . The mean time interval between the diagnosis of primary breast cancer and the appearance of gastric metastases usually ranges from 5 to 7 years [2, 6, 8] .
Abbreviations

CASE REPORT
Herein, we report the case of an 84-year-old female patient who presented to our department for dyspeptic symptoms. In her past medical and surgical history we noted a left mastectomy 20 years ago for lobular carcinoma of the breast that was estrogen receptors (ER) positive, progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) negative. She received adjuvant chemotherapy, radiotherapy and hormonal therapy. She was in complete remission on follow up and had surveillance with a yearly mammography. Her last mammography performed two months prior to her current presentation did not show any abnormalities. Her
symptoms started few months before seeking medical advice. She complained of dyspepsia and gastric fullness. She had no nausea, vomiting or epigastric pain.
On physical examination she had no palpable masses in the epigastrum or elsewhere in the abdomen, had no palpable nodules in her right breast and no palpable lymph nodes.
Gastroscopy revealed thickened gastric folds and diffuse infiltration of the stomach wall involving the fundus. There were no nodules, erosions, ulcers or stigmata of hemorrhage (Fig. 1) . Multiple mucosal blinded biopsies were taken.
Pathology showed proliferation of malignant, nonmucinous, poorly cohesive cells in a fibro-inflammatory stroma suggesting the diagnosis of primary, signet ring cell type, gastric adenocarcinoma. Given the past medical history, immunohistochemical analysis was done. Estrogen receptors were highly positive while PR and HER2 were negative. Cytokeratines (CK) 5 and 20 were negative and CK7 was positive. Anti-GATA-binding protein 3 (GATA3) nuclear antibodies were significantly positive on immunohistochemistry (IHC) staining and together with the previous findings confirmed the diagnosis of a metachronous metastasis of invasive lobular breast carcinoma to the stomach (Fig. 2) .
A computer tomography (CT) scan of the thorax and abdomen and a positron emission tomography (PET) scan did not show any other distant sites of metastases.
Hormonotherapy with Fulvestrant 500 mg every 28 days was started and digestive symptoms rapidly resolved.
DISCUSSION
In a review of 159 gastric metastases from breast adenocarcinoma, the mean age at diagnosis of the metastasis was 47 years whereas the median interval between the primary tumor and the secondary gastric location was 78 months (range, 33-96 months) [6] . Our patient was much older and had her primary breast lobular adenocarcinoma diagnosed 20 years earlier, which makes it an unusual case.
Symptoms are nonspecific and may range from dyspepsia (31%), loss of appetite, abdominal pain to vomiting and sometimes upper gastrointestinal tract obstruction [3, 6, 8] . Endoscopic findings are also nonspecific, as they may appear as mucosal ulcers, nodules, external compression and diffuse infiltration mimicking linitis plastica [6] . This latter is the most frequently described [9] , in up to 73% of the cases [10] .
In our case, the patient had dyspepsia and diffuse infiltrative appearance of the fundus on upper gastrointestinal endoscopy, which could have been thought to be primitive linitis plastica.
In this context, a past medical history of lobular breast cancer led to further workup and, if the initial biopsies would not have been contributory, more biopsies should have been done to get tissue from the deeper layers of the stomach and possibly endoscopic ultrasound-fine needle aspiration (EUS-FNA) for a good tissue diagnostic yield. In fact, metastases to the stomach usually spread to the submucosal layer with a diffuse infiltrative pattern on endoscopy, without destruction of the mucosa which can give rise to false negative biopsies in almost 10% of the cases [6, 11] .
Immunohistochemistry stain is crucial to differentiate primitive gastric cancer from metastatic disease in such cases. Many markers have been used, with ER and PR being mostly examined. Their positivity is suggestive of breast cancer; nevertheless, they can be positive in patients with cancer of gastric origin in 32% and 12% of the cases, respectively [12] . Knowing that their intense positivity is consistent with a diagnosis of metastasis of breast cancer [13] , this could make the latter the most probable in our case. Human epidermal growth factor receptor 2, which is expressed in 20% of gastric adenocarcinomas, is actually absent in lobular breast cancers [2, 3] and could thus reinforce our suspected diagnosis.
Gross Cystic Disease Fluid Protein-15 (GCDFP-15) and mammaglobin are two other markers that may also be used to characterize metastases from breast cancer, as they are expressed in 32-47% and 42-87% of the cases, respectively [14] [15] [16] . They have a high specificity, but low sensitivity [17] .
Recently, GATA3 emerged as a marker of urothelial and breast cancers. It has 100% positivity in breast lobular carcinoma and 96% positivity in breast ductal carcinoma. Only 5% of gastric malignant tumors stain positive for GATA3 [18] .
Our patient had diffuse strong nuclear expression of GATA3 which, along with a past medical history of invasive lobular breast carcinoma, CK5-/CK20-/CK7+, HER2 negativity and ER high positivity, can reliably confirm the diagnosis of a metachronous metastasis to the stomach, from invasive lobular breast adenocarcinoma.
CONCLUSION
Our case report supports the fact that considering gastric metastases from breast cancer and performing an upper gastrointestinal endoscopy are crucial in a patient presenting with any subtle gastric symptom and having a past medical history of breast adenocarcinoma even more than 20 years ago. If initial endoscopy and biopsies are negative, repeating them assisted by EUS-FNA for deep sampling might be necessary, to insure sufficient tissue yield. Adequate information should then be given to the pathologist for careful review of the specimen and specific IHC studies.
